MAIN ARTICLE
From manufacturing powerhouse to drug innovator
For decades, China’s position in global pharmaceuticals was associated with ingredients, active substances and large-scale manufacturing. The USCC’s 2026 annual report points to an evolving role: Chinese companies are increasingly developing therapies that major global drugmakers consider worth licensing. That shift matters because much of the sector’s value is generated not by factory volume alone, but through discovery, clinical testing, intellectual property and eventual regulatory approval. A company that can originate a promising medicine may command influence far beyond its domestic market.
Speaking during congressional discussions, USCC commissioner Leland Miller warned that China could emerge as an innovation center capable of challenging even the United States. That is a warning about trajectory, not evidence that China has already displaced American research leadership. U.S. universities, start-ups, investors and drug developers retain significant strengths in basic science, financing and the demanding process of bringing treatments to market. The central question is how those advantages will evolve as the geography of discovery broadens.
















